Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glycosaminoglycan silencing by engineered CXCL12 variants.

FEBS letters - 14 Sept 2015

Gschwandtner Martha, Trinker Martin U, Hecher Bianca, Adage Tiziana, Ali Simi, Kungl Andreas J

Abstract excerpt

We have engineered GPCR (G protein-coupled receptor) knock-out and high GAG-binding affinity into CXCL12α to inhibit CXCL12α-induced cell migration. Compared to wtCXCL12, the mutant CXCL12α (Δ8 L29K V39K) exhibited a 5.6-fold and a 2.2-fold affinity increase for heparin and heparan sulfate, respectively. From NaCl-based heparin displacement chromatography we concluded that more amino acid replacements would lead...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Silencing
Share to Cell Line, Tumor
Share to Chemokine CXCL12

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Glycosaminoglycans

Share to Protein Engineering

Share to Receptors, G-Protein-Coupled

Share to Signal Transduction

Source

Identifiers

PMID: 26297821
DOI: 10.1016/j.febslet.2015.07.052

Genes

CXCL12

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glycosaminoglycan silencing by engineered CXCL12 variants.PMID 26297821Read ↗

PEGylation of a glycosaminoglycan-binding, dominant-negative CXCL8 mutant retains bioactivity in vitro and in vivo.Semantic proximity Read ↗

Developing chemokine mutants with improved proteoglycan affinity and knocked-out GPCR activity as anti-inflammatory recombinant drugs.Semantic proximity Read ↗

Characterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans.Semantic proximity Read ↗

Functional divergence between 2 chemokines is conferred by single amino acid change.Semantic proximity Read ↗

C-terminal truncation of CXCL10 attenuates inflammatory activity but retains angiostatic propertiesSemantic proximity Read ↗

siRNA transfection and shRNA transduction optimization for CXCL12 mRNA silencing in human bone marrow mesenchymal stem cellsSemantic proximity Read ↗

CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10).Semantic proximity Read ↗

The potent anti-HIV activity of CXCL12gamma correlates with efficient CXCR4 binding and internalization.Semantic proximity Read ↗

Engineering the glycosaminoglycan-binding affinity, kinetics and oligomerization behavior of RANTES: a tool for generating chemokine-based glycosaminoglycan antagonists.Semantic proximity Read ↗

Llama-derived Single Variable Domains (Nanobodies) Directed against Chemokine Receptor CXCR7 Reduce Head and Neck Cancer Cell Growth in VivoSemantic proximity Read ↗

Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin.Semantic proximity Read ↗

Affinity Selection of FGF2-Binding Heparan Sulfates for Ex Vivo Expansion of Human Mesenchymal Stem CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.